Feature | Heart Valve Technology | March 14, 2017

Conscious Sedation TAVR Reduced Length-of-Stay and Hospital Costs

Minneapolis Heart Institute Foundation quality improvement review reduced LOS and cost without affecting the safety and outcomes of the procedure

TAVR, TAVI, conscience sedation

March 14, 2017 — Transcatheter aortic valve replacement (TAVR) for aortic stenosis continues to evolve with the adoption of methods intended to maximize efficacy, safety and patient recovery. Researchers at the Valve Science Center at Minneapolis Heart Institute Foundation recently conducted quality improvement review to examine the impact of the use of minimal anesthesia with conscious sedation (CS) in patients with severe, symptomatic aortic stenosis (AS) undergoing TAVR.
 
Using a multidisciplinary collaboration, a program was initiated to perform transfemoral TAVR with CS to treat patients with native valve AS.  Clinical outcomes for the first 50 patients treated with CS were compared to 50 control patients who had undergone TAVR with general anesthesia (GA) immediately preceding CS implementation. The two patient groups were similar with respect to age, hemodynamic severity of AS, symptom status and frailty. However, in comparison to GA patients, those who had TAVR with CS had shorter median procedure time and hospital length-of-stay (LOS). Procedural success with TAVR and major adverse complications were similar between the groups.  Overall, implementation of TAVR with CS led to a $2,833 reduction in median total variable costs per treated patient. Researchers concluded the implementation of a multidisciplinary program that enabled TAVR to be performed with CS led to significant reductions in LOS and hospital costs, without affecting the effectiveness and safety of the procedure.
 
“The evidence and insight gathered in this analysis supports a novel shift in how we manage our transfemoral TAVR patient population going forward,”  said Marcus Burns, DNP, principal investigator at the Minneapolis Heart Institute Foundation. “Conscious sedation, with its ability to maximize the ease of recovery from TAVR procedures, is a huge advancement for the many patients afflicted with aortic stenosis who seek treatment at our facility."  To date, researchers at the Valve Science Center at Minneapolis Heart Institute Foundation have performed more than 120 conscious sedation TF-TAVR’s since February 2016. “While interest in using conscious sedation for TAVR is steadily growing and a majority of centers have not yet adopted or just are beginning to adopt this approach in its true form," Burns explained.
 
The researchers will present their results at the American College of Cardiology (ACC) annual scientific session and expo this month.

Read the article “Moderate Sedation Shows Promise for TAVR Patients.”

Watch the VIDEO "The State of TAVR in 2016."

 

Related Content

CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Healthcare cybersecurity concerns have increased dramatically as EMRs and medical devices become more digitally connected.

Healthcare cybersecurity concerns have increased dramatically as EMRs and medical devices become more digitally connected.

Feature | Cybersecurity| August 18, 2017 | Dave Fornell
August 17, 2017 — Cybersecurity has become a growing concern in healthcare as patient data, medical systems and impla
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Overlay Init